John Parkinson

B.1.1.7, or otherwise known as VOC 202012/01, may lead to a large increase in the number of COVID-19 cases in the United States and may become the dominant strain of the virus in the coming months.

The single dose investigational vaccine being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson is a recombinant, replication-incompetent adenovirus serotype 26 vector encoding a stabilized SARS-CoV-2 spike protein.

The FDA will review a Biologics License Application for V114, Merck’s investigational 15-valent pneumococcal conjugate vaccine, for the prevention of invasive pneumococcal disease.

Trial that is evaluating the efficacy, safety, and immunogenicity of NVX-CoV2373 in COVID-19 is expected to be fully enrolled by the end of November.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.